Neutralization Synergy of Human Immunodeficiency Virus Type 1 Primary Isolates by Cocktails of Broadly Neutralizing Antibodies
Open Access
- 15 December 2001
- journal article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 75 (24) , 12198-12208
- https://doi.org/10.1128/jvi.75.24.12198-12208.2001
Abstract
Several reports have described the existence of synergy between neutralizing monoclonal antibodies (MAbs) against human immunodeficiency virus type 1 (HIV-1). Synergy between human MAbs b12, 2G12, 2F5, and 4E10 in neutralization of primary isolates is of particular interest. Neutralization synergy of these MAbs, however, has not been studied extensively, and the mechanism of synergy remains unclear. We investigated neutralization synergy among this human antibody set by using the classical approach of titrating antibodies mixed at a fixed ratio as well as by an alternative, variable ratio approach in which the neutralization curve of one MAb is assessed in the presence and absence of a fixed, weakly neutralizing concentration of a second antibody. The advantage of this second approach is that it does not require mathematical analysis to establish synergy. No neutralization enhancement of any of the MAb combinations tested was detected for the T-cell-line-adapted molecular HIV-1 clone HxB2 using both assay formats. Studies of primary isolates (89.6, SF162, and JR-CSF) showed neutralization synergy which was relatively weak, with a maximum of two- to fourfold enhancement between antibody pairs, thereby increasing neutralization titers about 10-fold in triple and quadruple antibody combinations. Analysis of b12 and 2G12 binding to oligomeric envelope glycoprotein by using flow cytometry failed to demonstrate cooperativity in binding between these two antibodies. The mechanism by which these antibodies synergize is, therefore, not yet understood. The results lend some support to the notion that an HIV-1 vaccine that elicits moderate neutralizing antibodies to multiple epitopes may be more effective than hereto supposed, although considerable caution in extrapolating to a vaccine situation is required.Keywords
This publication has 92 references indexed in Scilit:
- Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In VitroJournal of Virology, 2001
- Generation and Structural Analysis of Soluble Oligomeric gp140 Envelope Proteins Derived from Neutralization-Resistant and Neutralization-Susceptible Primary HIV Type 1 IsolatesAIDS Research and Human Retroviruses, 2000
- Erratum to “Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design” [Immunol. Lett. 57 (1997) 105–112]Immunology Letters, 1997
- A Dual-Tropic Primary HIV-1 Isolate That Uses Fusin and the β-Chemokine Receptors CKR-5, CKR-3, and CKR-2b as Fusion CofactorsCell, 1996
- Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5AIDS, 1996
- Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation.The Journal of Experimental Medicine, 1996
- Efficient Neutralization of Primary Isolates of HIV-1 by a Recombinant Human Monoclonal AntibodyScience, 1994
- Synergistic Inhibition of HIV-1 Envelope-Mediated Cell Fusion by CD4-Based Molecules in Combination with Antibodies to gp120 or gp41AIDS Research and Human Retroviruses, 1993
- Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120AIDS Research and Human Retroviruses, 1992
- COMBO: A New Approach to the Analysis of Drug Combinations in VitroaAnnals of the New York Academy of Sciences, 1990